secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001213900-25-112136
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve option repricing to $1.50; CTAD presentations set for Dec 1-4
--------------------------------------------------------------------------------

- Special meeting approves repricing of up to 5,511,000 outstanding stock options for employees, execs, and directors to $1.50 per share.
- Voting results: 7,144,433 for, 2,926,973 against, 121,836 abstentions.
- Repricing effective Nov 18; exercise price set at closing price of $1.50 on Nasdaq that day.
- Two presentations at CTAD conference Dec 1-4: Phase 2 MINDFuL trial results for XPro1595 in early Alzheimer’s, and EMACC validation.
- Phase 2 trial data on selective soluble TNF neutralizer XPro1595 to be presented as a poster.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025112136/0001213900-25-112136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025112136/ea0266048-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-112136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer